BioSpace News Archive

Antares Pharma, Inc. today announced positive results from a Phase I study for ATRS-1902 for adrenal crisis.

KemPharm, Inc., announced that research involving serdexmethylphenidate, the company’s proprietary prodrug of d-methylphenidate, will be featured in two poster presentations during the American Professional Society of ADHD and Related Disorders 2022 Annual Conference being held virtually January 13-16, 2022.

Sporos Bioventures, LLC today announced the formation of a Strategic Advisory Board (SAB), consisting of renowned scientific and business leaders in precision oncology and immunology research, drug discovery, clinical development, corporate development, and commercialization.

The eye care nonprofit Orbis International announces its collaboration on new research published in the latest issue of the top-tier peer-reviewed medical journal PLOS ONE.

Kineta, Inc., a clinical stage biotechnology company focused on the development of novel immunotherapies in oncology, announced that Kineta’s management team has been invited to participate at H.C. Wainwright Bioconnect Virtual Conference that is being held on January 10-13, 2022.

Aramis Biosciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for A197 enabling the company to proceed with a Phase II proof of concept clinical trial.

H-CYTE, Inc. (OTCQB: HCYT), a medical biosciences company, today announced that it has entered into a letter of intent for the acquisition of Catheter Precision, Inc.

The Geistlich Medical business unit of Geistlich Pharma AG, a family owned, Swiss-based global leader in regenerative solutions, is proud to announce the results from their clinical study of the Geistlich Derma-Gide® Advanced Wound Matrix.

BigHat Biosciences, Inc., a biotechnology company with an artificial intelligence/machine learning-guided antibody discovery and development platform, today announced the successful completion of the first stage of a previously undisclosed research collaboration and licensing agreement with Amgen applying BigHat’s platform for multi-objective optimization of a next-generation antibody.

Neogene Therapeutics, Inc. today announced an exclusive, worldwide license agreement with the National Cancer Institute (NCI) for a portfolio of TCRs targeting KRAS and TP53 mutations for the treatment of patients with cancer.